3 Undervalued Asian Small Caps With Notable Insider Buying

Amidst a backdrop of mixed economic signals and geopolitical tensions, Asian markets have shown resilience, with small-cap indices reflecting both challenges and opportunities. In this environment, identifying promising small-cap stocks often involves looking at insider buying trends as a potential indicator of confidence in the company's future prospects.

Top 10 Undervalued Small Caps With Insider Buying In Asia

Name	PE	PS	Discount to Fair Value	Value Rating
Australian Finance Group	7.7x	0.3x	21.67%	★★★★★☆
Ho Bee Land	13.2x	2.7x	43.06%	★★★★★☆
DMCI Holdings	6.3x	1.0x	41.10%	★★★★☆☆
Domino's Pizza Enterprises	NA	0.9x	14.78%	★★★★☆☆
ReadyTech Holdings	NA	1.5x	46.98%	★★★★☆☆
Aztech Global	13.0x	1.1x	-107.53%	★★★☆☆☆
China Yongda Automobiles Services Holdings	NA	0.0x	-63.49%	★★★☆☆☆
Growthpoint Properties Australia	16.7x	4.5x	19.00%	★★★☆☆☆
Hong Fok	23.8x	6.9x	29.70%	★★★☆☆☆
Paragon Care	NA	0.1x	-8.00%	★★★☆☆☆

Click here to see the full list of 52 stocks from our Undervalued Asian Small Caps With Insider Buying screener.

Let's dive into some prime choices out of from the screener.

4DMedical (ASX:4DX)

Simply Wall St Value Rating: ★★★☆☆☆

Overview: 4DMedical is a medical technology company specializing in the research and development of lung function analysis, with a market cap of A$111.76 million.

Operations: The company's revenue primarily stems from its Medical Technology R&D of Lung Function Analysis, with a recent gross profit margin of 93.77%. Operating expenses are significant, including general and administrative costs that reached A$39.24 million in the latest period.

PE: -10.2x

4DMedical, a small-cap company in Asia, has been making strides with its CT:VQ technology, now approved by the Therapeutic Goods Administration for commercial deployment across Australia. This software-based solution enhances lung imaging without requiring nuclear medicine infrastructure. Despite reporting a net loss of A$204 million for the year ending June 2026, insider confidence is evident through recent share purchases. The strategic partnership with Azra AI aims to integrate advanced patient-identification platforms into their offerings, potentially boosting future growth and market presence.

• Take a closer look at 4DMedical's potential here in our valuation report.

• Gain insights into 4DMedical's past trends and performance with our Past report.

Karrie International Holdings (SEHK:1050)

Simply Wall St Value Rating: ★★★☆☆☆

Overview: Karrie International Holdings is engaged in the production and distribution of storage products, EV charger enclosures, and server enclosures, with a market capitalization of HK$1.55 billion.

Operations: Karrie International Holdings generates revenue primarily from server enclosures, storage products, and EV charger enclosures. The gross profit margin has shown an upward trend, reaching 15.83% by the end of 2025. Operating expenses include sales and marketing as well as general and administrative costs, impacting the net income margin which was recorded at 6.99% in December 2025.

PE: 15.6x

Karrie International Holdings, a small player in the Asian market, has shown promising financial growth with sales reaching HK$3.47 billion and net income climbing to HK$270.88 million for the year ending March 2026. Despite relying solely on external borrowing for funding, which adds risk, insider confidence is evident as insiders have been buying shares throughout 2026. The company proposed a dividend increase to HK$0.045 per share, reflecting optimism about future earnings growth projected at 25% annually.

• Get an in-depth perspective on Karrie International Holdings' performance by reading our valuation report here.

• Examine Karrie International Holdings' past performance report to understand how it has performed in the past.

Aspial Lifestyle (SGX:5UF)

Simply Wall St Value Rating: ★★★☆☆☆

Overview: Aspial Lifestyle operates in retail, pawnbroking, and secured lending sectors with a market capitalization of S$0.15 billion.

Operations: The company generates revenue primarily from retail, pawnbroking, and secured lending. Retail is the largest segment with significant contributions to overall revenue. The gross profit margin has shown variability over time, reaching 37.46% in the most recent period.

PE: 7.2x

Aspial Lifestyle stands out in Asia's smaller market segment with its recent financial performance and insider confidence. The company reported a significant rise in sales to S$464 million for the first half of 2026, alongside net income nearly doubling to S$52 million. Non-Executive Chairman Wee Seng Koh's acquisition of 1.8 million shares, valued at approximately S$716,000, indicates strong belief in the company's potential. Despite relying on higher-risk external funding, earnings are projected to grow annually by over 6%.

• Click here to discover the nuances of Aspial Lifestyle with our detailed analytical valuation report.

• Review our historical performance report to gain insights into Aspial Lifestyle's's past performance.

Where To Now?

• Embark on your investment journey to our 52 Undervalued Asian Small Caps With Insider Buying selection here.
• Invested in any of these stocks? Simplify your portfolio management with Simply Wall St and stay ahead with our alerts for any critical updates on your stocks.
• Enhance your investing ability with the Simply Wall St app and enjoy free access to essential market intelligence spanning every continent.

Ready To Venture Into Other Investment Styles?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com